<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD>
<META content="text/html; charset=iso-8859-1" http-equiv=Content-Type>
<META name=GENERATOR content="MSHTML 8.00.6001.19046">
<STYLE></STYLE>
</HEAD>
<BODY>
<DIV><FONT size=2 face=Arial>Hello Professor Shaw and others,</FONT></DIV>
<DIV><FONT size=2 face=Arial>I am writing this from Cellabs Pty Ltd, Sydney
Australia. We have successfully developed exo-antigen based antibody detection
ELISA . The concept behind the exo-antigen is given under a separate
paragraph. </FONT></DIV>
<DIV><FONT size=2 face=Arial></FONT> </DIV>
<DIV><FONT size=2 face=Arial>Our ELISA system is an indirect one and we
use a monoclonal anti-human IgG as an indicator
antibody. By using this system we have succesfully demonstrated
presence of antibodies in serum samples against cutaneous
leishmaniases. </FONT><FONT size=2 face=Arial>I have not published the
results as yet but we have done quite a large study involving serum samples from
different countries including Brazil. I wanted to include serum samples from
Isreal and Indian subcontinent. I am unable to get these samples from these
countries. </FONT></DIV>
<DIV><FONT size=2 face=Arial></FONT> </DIV>
<DIV><FONT size=2 face=Arial>Our evaluation included samples from Brazil,
Colombia, Panama, Mexico, and Peru. One thing I have observed is that the
mucocutaneous condition certainly generates a high titre antibody than other
cutaneous conditions. With this we can conclude that the Th-2 response may
be very active during MCL. On the other hand, some investigator while
using our system has observed that the "CL-condition" from Iran did
not generate detectable antibodies. Why it is so I don't know.
We have not been given the samples for re-testing and no clinical data was
supplied to us. The way our correspondence went on - I led to
conclude that the so-called "CL- condition" from Iran may be highly
localised one and as yet not received a systemic response. That may be one of
the reasons for absence of antibodies in CL samples from Iran. My hyporthesis is
that here Th-1 may be in upper hand which might have nullified B-cell response.
</FONT></DIV>
<DIV><FONT size=2 face=Arial>[One has to prove this with immunological
evidence]. </FONT></DIV>
<DIV><FONT size=2 face=Arial>As you know, it is very diffcult for us in
Australia to obtain samples from these countries. </FONT></DIV>
<DIV><FONT size=2 face=Arial></FONT> </DIV>
<DIV><FONT size=2 face=Arial>So we have to be careful in generalising the
statement. Always there is tendency to state about a condition " muted
B-cell response" during CL condition. One has to investigate the
acutality of this myth. This is my opinion. As Professor Shaw has pointed
out that it is all dependent on the tools and devices we are using for
diagnosis of antibodies against cutaneous form of leishmania
infections. </FONT></DIV>
<DIV><FONT size=2 face=Arial></FONT> </DIV>
<DIV><FONT size=2 face=Arial>My answer went too long for this
session. </FONT></DIV>
<DIV><FONT size=2 face=Arial></FONT> </DIV>
<DIV><FONT size=2 face=Arial></FONT> </DIV>
<DIV><FONT size=2 face=Arial><STRONG>Concept behind EXOANTIGEN</STRONG>: These
antigens derive from active parasites maintained in serum- free and protein-
free condition. These antigens are released due to metabolic activity of the
parasites. Dr Samuel Martin of US-Army has conceived this idea.
The concept of using the exo- antigen is to
simulate the system operating within the infected individual where parasites are
active and undergoing multiplication and expelling their matabolic products.
Concurrently these products are being attacked by the immune system resulting
with many immune complexes within the body.</FONT></DIV>
<DIV><FONT size=2 face=Arial></FONT> </DIV>
<DIV><FONT size=2 face=Arial>I look forward to hear from other members on this
point.</FONT></DIV>
<DIV><FONT size=2 face=Arial></FONT> </DIV>
<DIV><FONT size=2 face=Arial>With best wishes</FONT></DIV>
<DIV><FONT size=2 face=Arial></FONT> </DIV>
<DIV><FONT size=2 face=Arial>Raj</FONT></DIV>
<DIV><FONT size=2 face=Arial>Dr G-Halli Rajasekariah</FONT></DIV>
<DIV><FONT size=2 face=Arial>Cellabs</FONT></DIV>
<DIV><FONT size=2 face=Arial></FONT> </DIV>
<DIV><FONT size=2 face=Arial></FONT> </DIV>
<DIV><FONT size=2 face=Arial>----- Original Message ----- </FONT>
<DIV><FONT size=2 face=Arial>From: <</FONT><A
href="mailto:leish-l-request@lineu.icb.usp.br"><FONT size=2
face=Arial>leish-l-request@lineu.icb.usp.br</FONT></A><FONT size=2
face=Arial>></FONT></DIV>
<DIV><FONT size=2 face=Arial>To: <</FONT><A
href="mailto:leish-l@lineu.icb.usp.br"><FONT size=2
face=Arial>leish-l@lineu.icb.usp.br</FONT></A><FONT size=2
face=Arial>></FONT></DIV>
<DIV><FONT size=2 face=Arial>Sent: Wednesday, May 18, 2011 1:00 AM</FONT></DIV>
<DIV><FONT size=2 face=Arial>Subject: Leish-l Digest, Vol 41, Issue
5</FONT></DIV></DIV>
<DIV><FONT face=Arial><BR><FONT size=2></FONT></FONT></DIV><FONT size=2
face=Arial>> Send Leish-l mailing list submissions to<BR>> </FONT><A
href="mailto:leish-l@lineu.icb.usp.br"><FONT size=2
face=Arial>leish-l@lineu.icb.usp.br</FONT></A><BR><FONT size=2 face=Arial>>
<BR>> To subscribe or unsubscribe via the World Wide Web, visit<BR>>
</FONT><A href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"><FONT
size=2
face=Arial>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</FONT></A><BR><FONT
size=2 face=Arial>> or, via email, send a message with subject or body 'help'
to<BR>> </FONT><A href="mailto:leish-l-request@lineu.icb.usp.br"><FONT size=2
face=Arial>leish-l-request@lineu.icb.usp.br</FONT></A><BR><FONT size=2
face=Arial>> <BR>> You can reach the person managing the list at<BR>>
</FONT><A href="mailto:leish-l-owner@lineu.icb.usp.br"><FONT size=2
face=Arial>leish-l-owner@lineu.icb.usp.br</FONT></A><BR><FONT size=2
face=Arial>> <BR>> When replying, please edit your Subject line so it is
more specific<BR>> than "Re: Contents of Leish-l digest..."<BR>> <BR>>
<BR>> Today's Topics:<BR>> <BR>> 1. CL Antibodies (jeffrey
shaw)<BR>> <BR>> <BR>>
----------------------------------------------------------------------<BR>>
<BR>> Message: 1<BR>> Date: Mon, 16 May 2011 19:54:58 +0000<BR>> From:
jeffrey shaw <</FONT><A href="mailto:jayusp@hotmail.com"><FONT size=2
face=Arial>jayusp@hotmail.com</FONT></A><FONT size=2 face=Arial>><BR>>
Subject: [Leish-l] CL Antibodies<BR>> To: Leish-L <</FONT><A
href="mailto:leish-l@lineu.icb.usp.br"><FONT size=2
face=Arial>leish-l@lineu.icb.usp.br</FONT></A><FONT size=2
face=Arial>><BR>> Message-ID: <</FONT><A
href="mailto:COL101-W12DEF680383CD45DA37FEDCB8D0@phx.gbl"><FONT size=2
face=Arial>COL101-W12DEF680383CD45DA37FEDCB8D0@phx.gbl</FONT></A><FONT size=2
face=Arial>><BR>> Content-Type: text/plain; charset="iso-8859-1"<BR>>
<BR>> <BR>> The accepted idea of no antibodies in cutaneous leishamaniasis
is incorrect. They definitely do occur in some but not all cases. However, they
may be missed if the wrong antigen is used. The greatest chance of detecting
them is to use the homologous antigen.Jeffrey Shaw
<BR>> -------------- next part --------------<BR>> An
HTML attachment was scrubbed...<BR>> URL: <</FONT><A
href="http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110516/e701460f/attachment.html"><FONT
size=2
face=Arial>http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110516/e701460f/attachment.html</FONT></A><FONT
size=2 face=Arial>><BR>> <BR>> ------------------------------<BR>>
<BR>> _______________________________________________<BR>> Leish-l mailing
list<BR>> </FONT><A href="mailto:Leish-l@lineu.icb.usp.br"><FONT size=2
face=Arial>Leish-l@lineu.icb.usp.br</FONT></A><BR><FONT size=2 face=Arial>>
</FONT><A href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l"><FONT
size=2
face=Arial>http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</FONT></A><BR><FONT
size=2 face=Arial>> <BR>> <BR>> End of Leish-l Digest, Vol 41, Issue
5<BR>> **************************************<BR>> <BR>> <BR>>
<BR>> <BR>> =======<BR>> Email scanned by PC Tools - No viruses or
spyware found.<BR>> (Email Guard: 7.0.0.21, Virus/Spyware Database:
6.17530)<BR>> </FONT><A href="http://www.pctools.com/"><FONT size=2
face=Arial>http://www.pctools.com/</FONT></A><BR><FONT size=2 face=Arial>>
=======</FONT><br/><br/><br><br><FONT face="Tahoma" size="2"><br>=======<br>Email scanned by PC Tools - No viruses or spyware found.<br>(Email Guard: 7.0.0.21, Virus/Spyware Database: 6.17530)<br><a href=http://www.pctools.com/?cclick=EmailFooterClean_51>http://www.pctools.com</a><br>=======</FONT>
</BODY></HTML>